Base de dados : LILACS
Pesquisa : D03.383.725.150 [Categoria DeCS]
Referências encontradas : 14 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 14 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-741125
Autor: Faria, Ana Paula Cabral de; Modolo, Rodrigo; Moreno, Beatriz Vaz Domingues; Moreno, Heitor.
Título: Effects of PDE type 5 inhibitors on Left Ventricular Diastolic Dysfunction in Resistant Hypertension / Efeitos dos Inibidores da PDE do Tipo 5 sobre a Disfunção Diastólica Ventricular Esquerda na Hipertensão Arterial Resistente
Fonte: Arq. bras. cardiol;104(1):85-89, 01/2015. graf.
Idioma: en.
Resumo: Resistant hypertension (RHTN) is a multifactorial disease characterized by blood pressure (BP) levels above goal (140/90 mmHg) in spite of the concurrent use of three or more antihypertensive drugs of different classes. Moreover, it is well known that RHTN subjects have high prevalence of left ventricular diastolic dysfunction (LVDD), which leads to increased risk of heart failure progression. This review gathers data from studies evaluating the effects of phosphodiesterase-5 (PDE-5) inhibitors (administration of acute sildenafil and short-term tadalafil) on diastolic function, biochemical and hemodynamic parameters in patients with RHTN. Acute study with sildenafil treatment found that inhibition of PDE-5 improved hemodynamic parameters and diastolic relaxation. In addition, short-term study with the use of tadalafil demonstrated improvement of LVDD, cGMP and BNP-32 levels, regardless of BP reduction. No endothelial function changes were observed in the studies. The findings of acute and short-term studies revealed potential therapeutic effects of IPDE-5 drugs on LVDD in RHTN patients.

A Hipertensão arterial resistente (HAR) é uma doença multifatorial caracterizada por níveis pressóricos acima das metas (140/90 mmHg), a despeito de tratamento farmacológico otimizado de 3 ou mais fármacos anti-hipertensivos de diferentes classes. Pacientes diagnosticados como hipertensos resistentes apresentam alta prevalência de disfunção diastólica do ventrículo esquerdo (DDVE) que proporciona risco aumentado para insuficiência cardíaca. Esta revisão reúne dados de estudos prévios avaliando os efeitos dos inibidores de fosfodiesterase-5 (PDE-5) (administração aguda de sildenafil e de curto prazo de tadalafil) na função diastólica e nos parâmetros bioquímicos e hemodinâmicos em pacientes com HAR. O estudo agudo com sildenafil demonstrou que a inibição da PDE-5 melhorou os parâmetros hemodinâmicos e de relaxamento diastólico. Além disso, o estudo curto prazo com o uso de tadalafil revelou melhora da DDVE e dos níveis de GMPc e BNP-32, independente de redução de pressão arterial. A função endotelial não apresentou alteração com ambos os tratamentos. Os resultados dos estudos agudo e de curto prazo sugerem efeitos terapêuticos potenciais dos fármacos inibidores da PDE-5 na disfunção diastólica em pacientes com HAR.
Descritores: Insuficiência Cardíaca Diastólica/tratamento farmacológico
Hipertensão/tratamento farmacológico
/uso terapêutico
PHOSPHODIESTERASE ABDOMEN INHIBITORS/uso terapêutico
Disfunção Ventricular Esquerda/tratamento farmacológico
-Carbolinas/uso terapêutico
Resistência a Medicamentos
Diástole/efeitos dos fármacos
Insuficiência Cardíaca Diastólica/fisiopatologia
Hipertensão/fisiopatologia
Ilustração Médica
Piperazinas/uso terapêutico
Purinas/uso terapêutico
Citrato de Sildenafila
Sulfonamidas/uso terapêutico
Tadalafila
Resultado do Tratamento
Disfunção Ventricular Esquerda/fisiopatologia
Limites: Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Revisão
Responsável: BR1.1 - BIREME


  2 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-723954
Autor: Regadas, Rommel Prata; Reges, Ricardo; Cerqueira, João Batista Gadelha; Sucupira, Daniel Gabrielle; Jamacaru, Francisco Vagnaldo F.; Moraes, Manoel Odorico de; Gonzaga-Silva, Lúcio Flávio.
Título: Effects of chronic administration of tamsulosin and tadalafil, alone or in combination, in rats with bladder outlet obstruction induced by chronic nitric oxide deficiency
Fonte: Int. braz. j. urol;40(4):546-552, Jul-Aug/2014. tab, graf.
Idioma: en.
Resumo: Purpose The aim of this study was to define if tadalafil causes detrusor muscle impairment and to observe the effect of combination of tadalafil with tamsulosin on the lower urinary tract of rats with bladder outlet obstruction (BOO) induced by chronic nitric oxide deficiency. Materials and Methods Thirty-one male rats were randomized to following groups: 1 - control; 2 - L-Nitroarginine methyl ester (L-NAME); 3 - Tamsulosin + L-NAME, 4 Tadalafil+L-NAME; and 5 - Tamsulosin + Tadalafil + L-NAME. At the end of the treatment period (30 days), all animals were submitted to urodynamic study. Results The administration of L-NAME increased the number of non-voiding contractions (NVC) (1.04 ± 0.22), volume threshold (VT) (1.86 ± 0.35), and micturition cycle (MC) (1.34 ± 0.11) compared with control (0.52 ± 0.06, 0.62 ± 0.06, and 0.67 ± 0.30), respectively. The administration of tamsulosin reduced the number of NVC (0.57 ± 0.42) and VT (0.76 ± 0.24 ) compared with L-NAME group. Co-treatment with tadalafil decreased the number of VT (0.85 ± 0.53) and MC (0.76 ± 0.22) compared with L-NAME group. The combination of tamsulosin with tadalafil improved the number of NVC (0.56 ± 0.18), VT (0.97 ± 0.52) and MC (0.68 ± 0.30) compared with L-NAME group. Conclusion In rats with BOO induced by chronic nitric oxide deficiency, tadalafil did not cause impairment in detrusor muscle and seems to have an addictive effect to tamsulosin because the combination decreased non voiding contractions as well the number of micturition cycles. .
Descritores: Carbolinas/administração & dosagem
Sulfonamidas/administração & dosagem
Obstrução do Colo da Bexiga Urinária/tratamento farmacológico
Agentes Urológicos/administração & dosagem
-Quimioterapia Combinada
NG-Nitroarginina Metil Éster/administração & dosagem
Óxido Nítrico/deficiência
/administração & dosagem
PHOSPHODIESTERASE ABDOMEN INHIBITORS/administração & dosagem
Distribuição Aleatória
Ratos Wistar
Reprodutibilidade dos Testes
Resultado do Tratamento
Obstrução do Colo da Bexiga Urinária/etiologia
Micção/efeitos dos fármacos
Limites: Animais
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  3 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-718249
Autor: Cairoli, Carlos; Reyes, Luis Antonio; Henneges, Carsten; Sorsaburu, Sebastian.
Título: PDE5 Inhibitor Treatment Persistence and Adherence in Brazilian Men: Post-hoc Analyses from a 6-Month, Prospective, Observational Study
Fonte: Int. braz. j. urol;40(3):390-399, may-jun/2014. tab, graf.
Idioma: en.
Resumo: Purpose Characterize persistence and adherence to phosphodiesterase type - 5 inhibitor (PDE5I) on-demand therapy over 6 months among Brazilian men in an observational, non-interventional study of Latin American men naïve to PDE5Is with erectile dysfunction (ED). Materials and Methods Men were prescribed PDE5Is per routine clinical practice. Persistence was defined as using ≥ 1 dose during the previous 4 - weeks, and adherence as following dosing instructions for the most recent dose, assessed using the Persistence and Adherence Questionnaire. Other measures included the Self - Esteem and Relationship (SEAR) Questionnaire, and International Index of Erectile Function (IIEF). Multivariate logistic regression was used to identify factors associated with persistence/adherence. Results 104 Brazilian men were enrolled; mean age by treatment was 53 to 59 years, and most presented with moderate ED (61.7%). The prescribed PDE5I was sildenafil citrate for 50 (48.1%), tadalafil for 36 (34.6%), vardenafil for 15 (14.4%), and lodenafil for 3 patients (2.9%). Overall treatment persistence was 69.2% and adherence was 70.2%; both were numerically higher with tadalafil (75.0%) versus sildenafil or vardenafil (range 60.0% to 68.0%). Potential associations of persistence and/or adherence were observed with education level, ED etiology, employment status, and coronary artery disease. Improvements in all IIEF domain scores, and both SEAR domain scores were observed for all treatments. Study limitations included the observational design, brief duration, dependence on patient self - reporting, and limited sample size. Conclusion Approximately two-thirds of PDE5I-naive, Brazilian men with ED were treatment persistent and adherent after 6 months. Further study is warranted to improve long-term outcomes of ED treatment. .
Descritores: Disfunção Erétil/tratamento farmacológico
Adesão à Medicação
/uso terapêutico
PHOSPHODIESTERASE ABDOMEN INHIBITORS/uso terapêutico
-Brasil
Carbolinas/uso terapêutico
Escolaridade
Imidazóis/uso terapêutico
Satisfação do Paciente
Estudos Prospectivos
Piperazinas/uso terapêutico
Purinas/uso terapêutico
Estatísticas não Paramétricas
Inquéritos e Questionários
Sulfonas/uso terapêutico
Fatores de Tempo
Resultado do Tratamento
Triazinas/uso terapêutico
Limites: Adulto
Idoso
Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  4 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-697686
Autor: Barreto, Monique Antunes de Souza Chelminski; Bahmad Jr, Fayez.
Título: Inibidores da fosfodiesterase do tipo 5 e perda auditiva neurossensorial subita / Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
Fonte: Braz. j. otorhinolaryngol. (Impr.);79(6):727-733, Nov-Dec/2013. tab.
Idioma: pt.
Resumo: O uso de inibidores da fosfodiesterase do tipo 5 como sildenafil, vardenafil e tadalafil tem aumentado atualmente e alguns destes pacientes vêm apresentando perda auditiva neurossensorial súbita. OBJETIVO: Apresentar dois casos de pacientes que apresentaram surdez súbita em uso eventual do medicamento e revisar estudos sobre o uso de inibidores da fosfodiesterase do tipo 5 e surdez súbita. MÉTODO: Estudo analítico de dois casos e revisão sobre o tema no banco de dados da Pubmed/ MedLine e Bireme utilizando as palavras-chave inibidores da fosfodiesterase e surdez súbita e seus correlatos na língua inglesa. RESULTADOS: Os pacientes analisados são jovens, sem comorbidades, em uso de inibidores da fosfodiesterase do tipo 5 e após terapia combinada para o tratamento da surdez súbita, apenas um deles obteve melhora auditiva. Nove estudos científicos foram encontrados. Estudos pré-clínicos e clínicos, transversais e prospectivos foram revisados. CONCLUSÃO: O aumento da ocorrência na prática clínica e relatos científicos na literatura sugerem que o uso de inibidores da fosfodiesterase do tipo 5 seja encarado como fator de risco para surdez súbita. Novos estudos com amostras maiores e grupo controle são necessários para investigar esta associação. .

Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been increasingly used today and some of the users have developed sudden sensorineural hearing loss. OBJECTIVE: To present two patients with sudden deafness developed after an occasional use of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and sudden hearing loss. METHOD: Analytical study of two cases and review of the subject matter in the Pubmed/Medline and Bireme databases using the keywords: phosphodiesterase type 5 inhibitors and sudden deafness and its correlates in the English language. RESULTS: The patients analyzed are young without additional disorders, using phosphodiesterase type 5 inhibitors, and after combination treatment for sudden hearing loss only one had hearing improvement. We found nine scientific studies and reviewed preclinical studies, clinical trials, prospective and cross-sectional investigations. CONCLUSION: Increased occurrence in clinical practice and scientific reports in the literature suggest that the phosphodiesterase type 5 inhibitors are considered a risk factor for sudden deafness. Further studies with larger samples and control groups are needed for better assessing this association. .
Descritores: Carbolinas/uso terapêutico
Perda Auditiva Neurossensorial/tratamento farmacológico
Perda Auditiva Súbita/tratamento farmacológico
Imidazóis/uso terapêutico
/uso terapêutico
PHOSPHODIESTERASE ABDOMEN INHIBITORS/uso terapêutico
Piperazinas/uso terapêutico
Sulfonas/uso terapêutico
-Quimioterapia Combinada
Purinas/uso terapêutico
Resultado do Tratamento
Triazinas/uso terapêutico
Limites: Adulto
Humanos
Masculino
Tipo de Publ: Relatos de Casos
Revisão
Responsável: BR1.1 - BIREME


  5 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-696149
Autor: Alfonzo Núñez, Ricardo; Cardozo Madrid, Orlando; García, Douglas; Bacarani, Daniel.
Título: Tratamiento médico de la fisura anal con tadafilo tópico como principio activo / Medical treatment of chronic anal fissure with topical tadalafil
Fonte: Rev. argent. coloproctología;23(1):32-36, mar. 2012. tab.
Idioma: es.
Resumo: Introducción: La fisura anal es una úlcera lineal dolorosa que generalmente, aparece en la línea media posterior del canal anal, extendiéndose desde la línea dentada hasta el margen del ano. Su persistencia se debe al espasmo anómalo del músculo del esfínter interno. Hasta hace poco, la curación definitiva de las fisuras solo se logró mediante procedimientos quirúrgicos dirigidos a la ablación del espasmo esfinteriano. Diseño: Estudio prospectivo, controlado y aleatorio para comprobar la hipótesis de que la aplicación tópica de una preparación de Tadalafilo es un método efectivo y seguro para relajar el músculo liso y promover la cicatrización de la fisura anal. Población y métodos: Se seleccionaron los pacientes que acudieron a la consulta de coloproctología del HCC con diagnóstico de fisura anal (726). Todos fueron sometidos a una historia clínica y examen físico, antes del comienzo del tratamiento y seguimiento por 1 año. Los pacientes fueron divididos en tres grupos: Grupo A: tratados de forma médica con AINES por via oral, sediluvios y pomadas tópicas de esteroides 3 veces al dia. Grupo B: tratados con nitroglicerina 0,25% locales crema 3 veces al día. Grupo C: tratados con toxina botulínica inyectada 1 sola dosis en el espesor del esfínter interno del ano. Grupo D: tratados con formula magistral crema tópica de Tadalafilo aplicada 3 veces al día. Grupo E: pacientes a quienes se les realiza la Esfinterotomía Lateral Interna una vez que se considera ha fracasado el manejo médico y tratamiento farmacológico. Resultados: Se encontró predominio del sexo femenino con 370 pacientes (50.97%). Las edades en las cual se agrupó mayor cantidad de individuos fue entre los 26 a 35 años con 218 pacientes (30,02%). Predominó el diagnóstico de fisura crónica con 382 casos (52,61 %). El tratamiento inicial que se utilizó más frecuentemente fue el quirúrgico con 270 pacientes (37,19%), seguido de Tadalafilo tópico con 196 pacientes (26,99%)...

Introduction: Anal fissure is a painful linear ulcer usually appears in the posterior midline of the anal canal, extending from the dentate line to the margin of the anus. Its persistence is due to spasm abnormal internal sphincter muscle. Until recently, a definitive cure was achieved only cracks by surgical procedures aimed at ablation of the sphincter spasm. Design: Prospective. controlled trial to test the hypothesis that topical application of a preparation of Tadalafil is a safe and effective method to relax the smooth muscle and promote healing of anal fissure. Population and methods: We selected patients who attended the consultation of Coloproctology of HCC diagnosed with anal fissure (726). AIl underwent a medical history and physical examination before starting treatment and followed for 1 year. The patients were divided into three groups: Group A: treated medical oral NSAlDs, topical ointments sediluvios and steroids 3 times a day. Group B: treated with local nitroglycerin cream 0.25% 3 times a day. Group C: treated with botulinum toxin injection 1 dose in the thickness of the internal anal sphincter. Group D: treated with topical cream formulation TadalafiI masterfully applied 3 times a day. Group E: patients who underwent lateral internal sphincterotomy is considered after failed medical management and pharmacological treatment. Results: There was a predominance of females with 370 patientes (50.97%). The ages at which more individuals grouped was between 26 to 35 years with 218 patients (30.02%). The predominant diagnosis of chronic fissure with 382 cases (52.61%). The initial treatment was most frequently used surgical treatment of 270 patients (37.19%), followed by topical Tadalafil 196 patients (26.99%). The initial treatment had less failure was the use of topical Tadalafil 10 cases (1.37%), which required surgery...
Descritores: Carbolinas/administração & dosagem
Fissura Anal/tratamento farmacológico
Fissura Anal/terapia
-Administração Tópica
Carbolinas/uso terapêutico
Esfinterotomia Endoscópica/métodos
Nitroglicerina/uso terapêutico
Distribuição por Sexo
Resultado do Tratamento
Toxinas Botulínicas/administração & dosagem
Toxinas Botulínicas/uso terapêutico
Limites: Humanos
Masculino
Adulto
Feminino
Responsável: AR1.1 - Biblioteca Rafael Herrera Vegas


  6 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-686522
Autor: Bjekic, Milan; Markovic, Milica; Sipetic, Sandra.
Título: Fixed drug eruption caused by tadalafil - case report / Erupcao fixa por droga provocada por tadalafil - relato de caso
Fonte: An. bras. dermatol;88(4):617-619, ago. 2013. graf.
Idioma: en.
Projeto: Ministry for Science and Technology of Serbia.
Resumo: Fixed drug eruptions (FDE) are commonly reported type of mucocutaneous drug eruption. The aim of this paper is to present a patient with multiple mucocutaneous erythema fixum type lesions caused by oral tadalafil use. A short course of topical corticosteroid therapy resulted in complete resolution of all lesions leaving residual hyperpigmentation of the involved skin sites. Mucosal oral lesions were effectively treated with gingival hyaluronic acid 0.2% gel. Conclusion: when assessing a patient of any age with drug eruptions, a thorough personal history should be obtained, in particular data on regular or recreational use of phospodiesterase type 5 inhibitors.

A erupção fixa por droga é um tipo de erupção mucocutânea comumente relatada, provocada pela administração de de drogas. O objetivo deste artigo é apresentar um paciente com múltiplas lesões mucocutâneas do tipo do eritema fixo, causadas pelo uso do tadalafil oral. Um breve período de tratamento com corticosteroides tópicos levou à completa resolução de todas as lesões, deixando hiperpigmentação residual nas áreas cutâneas envolvidas. As lesões da mucosa oral foram tratadas efetivamente com gel de ácido hialurônico gengival a 0,2%. Conclusão: ao avaliar o paciente com erupção fixa por druga, de qualquer idade, deve ser obtido seu histórico pessoal completo, especialmente dados sobre uso regular ou recreativo de inibidores de fosfodiesterase tipo 5.
Descritores: Carbolinas/efeitos adversos
Erupção por Droga/etiologia
/efeitos adversos
PHOSPHODIESTERASE ABDOMEN INHIBITORS/efeitos adversos
-Corticosteroides/uso terapêutico
Erupção por Droga/tratamento farmacológico
Resultado do Tratamento
Limites: Adulto
Humanos
Masculino
Tipo de Publ: Relatos de Casos
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-663714
Autor: Ortiz, Isabel C; Peláez, Carlos A; Orozco, Luz Yaneth; Zuleta, Margarita.
Título: Interacciones genotóxicas de mutágenos en mezclas binarias mediante ensayo cometa alcalino en linfocitos humanos / Interaction of mutagens in binary mixtures using the alkaline comet assay in human lymphocytes
Fonte: Biomédica (Bogotá);32(3):437-448, jul.-set. 2012. ilus, tab.
Idioma: es.
Resumo: Introducción. Los mutágenos contenidos en mezclas complejas presentan interacciones de sinergismo, aditivas o antagónicas. Se han desarrollado enfoques experimentales que permitan dilucidar el responsable de las interacciones en la mezcla. Objetivo. Desarrollar un diseño experimental para comprender los procesos que se llevan a cabo entre los compuestos presentes en las mezclas complejas. Materiales y métodos. Se expusieron linfocitos humanos a mezclas binarias de mutágenos B[a]P, DMBA, Trp-P-1 y MX durante una hora, con activación metabólica y sin ella. La viabilidad se evaluó con azul de tripano y, la genotoxicidad, con cometa alcalino. Resultados. Ningún hidrocarburo tuvo efecto con furanona. Con S9 y sin él, se observó que se presentaban interacciones tóxicas entre hidrocarburos. Se observó sinergismo sin S9 entre B[a]P y Trp-P-1 y, con actividad metabólica, entre DMBA y Trp-P-1. Sin S9 se observó interacción antagónica entre Trp-P-1 y DMBA y, con S9, entre Trp-P-1 y MX y entre MX y DMBA. Se observó un incremento dependiente de la dosis en la longitud de la cola. Hubo daño genotóxico medio y aumento de las células dañadas. Para todas las mezclas se pudo determinar la concentración mínima en la que se observaban efectos adversos y solo para algunas se determinó la concentración máxima en la cual no se observaron efectos adversos. Conclusión. Se hace un aporte para comprender los procesos que ocurren cuando en una mezcla hay presentes, al menos, dos mutágenos y se valida un modelo de análisis que permite dilucidar el compuesto que tiene efecto sobre otro. También, se demostró que según el tipo de compuestos en la mezcla, se tendrá o no un umbral de riesgo.

Introduction. Mutagens contained in complex mixtures can present synergistic interactions, either additive or antagonistic. Therefore, development of experimental approaches is necessary to elucidate which is the responsible agent for the effect in the mixtures. Objective. An experimental design was developed that allowed an understanding of the processes between the compounds of complex mixtures. Materials and methods. Human lymphocytes were exposed to binary mixtures of the mutagens B[a]P, DMBA, Trp-P-1 and MX for 1 hour with or without S9. Viability was assessed with trypan blue dye and the genotoxicity by the comet assay. Results. All of the hydrocarbon showed an effect with furanone. With and without S9, the most toxic interactions were observed between hydrocarbons. Synergistic interaction was observed without S9 between B [a] P and Trp-P-1 and between DMBA and Trp-P-1 with metabolic activity. Without S9 antagonistic interaction was observed only between Trp-P-1+DMBA, and with S9 between Trp-P-1+MX and MX+DMBA. It observed an increase dose dependent in tail length. Half the cultures showed genotoxic damage and increased cell damage. For each mixture, minimum concentrations were determined at which adverse effects are observed; for some only the maximum concentration was determined at which no adverse effects are observed. Conclusion. The processes between mutagens present in a mixture have become better understood, and the results validated an analytical model that determined which component had an effect on another. The results also showed that the type of compounds in the mixture determined whether or not a risk threshold was present.
Descritores: Ensaio Cometa
Técnicas In Vitro
Linfócitos/efeitos dos fármacos
Mutagênicos/toxicidade
-/administração & dosagem
9,ABDUCENS NERVE-DIMETHYL-1,TEMEFOS-BENZANTHRACENE/administração & dosagem
/farmacologia
9,ABDUCENS NERVE-DIMETHYL-1,TEMEFOS-BENZANTHRACENE/farmacologia
/toxicidade
9,ABDUCENS NERVE-DIMETHYL-1,TEMEFOS-BENZANTHRACENE/toxicidade
Biotransformação
Benzo(a)pireno/administração & dosagem
Benzo(a)pireno/farmacologia
Benzo(a)pireno/toxicidade
Sobrevivência Celular
Carbolinas/administração & dosagem
Carbolinas/farmacologia
Carbolinas/toxicidade
Células Cultivadas/efeitos dos fármacos
Células Cultivadas/ultraestrutura
Dano ao DNA
Interações Medicamentosas
Furanos/administração & dosagem
Furanos/farmacologia
Furanos/toxicidade
INHIBITORY CONCENTRATION ACADEMIES AND INSTITUTES
Linfócitos/ultraestrutura
Microssomos Hepáticos/metabolismo
Mutagênicos/administração & dosagem
Mutagênicos/farmacologia
Limites: Adulto
Humanos
Masculino
Tipo de Publ: Estudo Comparativo
Research Support, Non-U.S. Gov't
Responsável: CO332 - Facultad de Medicina


  8 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-623312
Autor: Madani, Ali Hamidi; Afsharimoghaddam, Amin; Roushani, Ali; Farzan, Alireza; Asadollahzade, Ahmad; Shakiba, Maryam.
Título: Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
Fonte: Int. braz. j. urol;38(1):33-39, Jan.-Feb. 2012. tab.
Idioma: en.
Resumo: OBJECTIVES: To evaluate safety and efficacy of tadalafil on lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in patients treated with standard medication. MATERIALS AND METHODS: In this case-controlled randomized clinical trial, from November 2008 to August 2009, 132 patients with obstructive and irritative urinary tract symptoms due to BPH, IPSS > 8, no indication for surgical intervention and that reached plateau levels of response to treatment were selected. These patients were randomly allocated in two groups (each containing 66 patients). The treatment group received standard treatment of BPH and tadalafil (10 mg nightly); the placebo group received only standard treatment of BPH. IPSS, maximum urinary flow rate (Qmax) and quality of life were assessed before and after a 3-month period of study. RESULTS: Before treatment, mean IPSS, Qmax and quality of life values in the treatment and placebo groups were 13.06 ± 4.37 and 13.66 ± 4.25, 8.92 ± 2.96 mL/s and 9.09 ± 2.91 mL/s, 2.93 ± 0.86 and 2.66 ± 0.78, respectively. After treatment, mean IPSS, Qmax, and quality of life values in treatment group were 7.66 ± 3.99, 9.99 ± 4.76 mL/s and 1.80 ± 0.98, respectively. These findings were compared to corresponding values of the placebo group (11.37 ± 3.64, 8.73 ± 2.22 mL/s and 2.19 ± 0.53, respectively): IPSS and quality of life were significantly different but Qmax didn't show a significant change. CONCLUSIONS: Tadalafil improves quality of life and urinary symptoms in patients with LUTS suggestive of BPH, but doesn't have any significant effect on Qmax. Therefore, this drug may be effectively used in combination with standard medical therapies for BPH.
Descritores: Carbolinas/uso terapêutico
Disfunção Erétil/tratamento farmacológico
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Inibidores de Fosfodiesterase/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
-Método Duplo-Cego
Placebos
Qualidade de Vida
Resultado do Tratamento
Limites: Idoso
Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  9 / 14 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-596008
Autor: Aydogdu, Ozgu; Gokce, Mehmet Ilker; Burgu, Berk; Baltaci, Sumer; Yaman, Onder.
Título: Tadalafil rehabilitation therapy preserves penile size after bilateral nerve sparing radical retropubic prostatectomy
Fonte: Int. braz. j. urol;37(3):336-346, May-June 2011. ilus, graf, tab.
Idioma: en.
Resumo: OBJECTIVE: To evaluate the change in penile size r bilateral nerve sparing retropubic radical prostatectomy (BNSRRP) and possible effect of Tadalafil. MATERIALS AND METHODS: A total of 65 patients underwent BNSRRP and they were evaluated prospectively for a whole year of follow-up . The patients were randomized to control without rehabilitation (Group 1) or Tadalafil rehabilitation group (Group 2). The patients were evaluated at months 3, 6 and 12 postoperatively for erectile function, penile measurements (flaccid penile length, penile length at maximum erection, penile circumference at flaccid status, and penile circumference at maximum erection), penile abnormalities and general health status. Statistical analysis was performed by Chi-Square test and significance was defined as p value < 0.05. RESULTS: In Group 1 there was significant decrease in penile measurements at month 3 compared to preoperative measurements. There was decrease in all parameters at month 6 compared to month 3 but only the decrease in penile length at maximum erection was significant. There were no significant differences between postoperative months 6 and 12 for all measurements. In Group 2 there was a tendency to decrease in all measurements at month 3 compared to baseline. There was no significant difference for penile measurements between postoperative 3rd and 6th months and between 6th month and the first year. CONCLUSION: Although further large sampled trials are needed to describe the possible positive effect of tadalafil or other PDE5-I's on penile size after BNSRRP, tadalafil rehabilitation is effective in preserving penile size especially in the early postoperative period after BNSRRP.
Descritores: Carbolinas/uso terapêutico
Pênis/anatomia & histologia
/uso terapêutico
PHOSPHODIESTERASE ABDOMEN INHIBITORS/uso terapêutico
Prostatectomia/reabilitação
-Distribuição de Qui-Quadrado
Tamanho do Órgão/efeitos dos fármacos
Tratamentos com Preservação do Órgão/métodos
Estudos Prospectivos
Ereção Peniana/efeitos dos fármacos
Ereção Peniana/fisiologia
Pênis/efeitos dos fármacos
Pênis/inervação
Prostatectomia/efeitos adversos
Fatores de Tempo
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Ensaio Clínico Controlado Aleatório
Responsável: BR1.1 - BIREME


  10 / 14 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-578570
Autor: Savas, Murat; Yeni, Ercan; Verit, Ayhan; Gulum, Mehmet; Aksoy, Nurten; Ciftci, Halil; Celik, Hakim; Altunkol, Adem; Oncel, Halil.
Título: Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
Fonte: Clinics;65(12):1311-1314, 2010. tab.
Idioma: en.
Resumo: OBJECTIVES: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. METHODS: Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. RESULTS: Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H2O2 Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H2O2 Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p<0.0001 for all). CONCLUSIONS: Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.
Descritores: Carbolinas/farmacologia
Dipeptidases/metabolismo
Disfunção Erétil/sangue
Disfunção Erétil/tratamento farmacológico
Estresse Oxidativo/efeitos dos fármacos
/farmacologia
PHOSPHODIESTERASE ABDOMEN INHIBITORS/farmacologia
-Estudos de Casos e Controles
Limites: Adulto
Humanos
Masculino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde